首页> 外文期刊>Cardiology in review >A Novel Class of Human Cardiac Stem Cells
【24h】

A Novel Class of Human Cardiac Stem Cells

机译:一类新型的人类心脏干细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Following the recognition that hematopoietic stem cells improve the outcome of myocardial infarction in animal models, bone marrow mononuclear cells, CD34-positive cells, and mesenchymal stromal cells have been introduced clinically. The intracoronary or intramyocardial injection of these cell classes has been shown to be safe and to produce a modest but significant enhancement in systolic function. However, the identification of resident cardiac stem cells in the human heart (hCSCs) has created great expectation concerning the potential implementation of this category of autologous cells for the management of the human disease. Although phase 1 clinical trials have been conducted with encouraging results, the search for the most powerful hCSC for myocardial regeneration is in its infancy. This manuscript discusses the efforts performed in our laboratory to characterize the critical biological variables that define the growth reserve of hCSCs. Based on the theory of the immortal DNA template, we propose that stem cells retaining the old DNA represent 1 of the most powerful cells for myocardial regeneration. Similarly, the expression of insulin-like growth factor-1 receptors in hCSCs recognizes a cell phenotype with superior replicating reserve. However, the impressive recovery in ventricular hemodynamics and anatomy mediated by clonal hCSCs carrying the mother DNA underscores the clinical relevance of this hCSC class for the treatment of human heart failure.
机译:在认识到造血干细胞可改善动物模型中心肌梗塞的预后后,临床上已引入了骨髓单个核细胞,CD34阳性细胞和间质基质细胞。已经证明,这些细胞类型的冠状动脉内或心肌内注射是安全的,并且在收缩功能方面产生适度但显着的增强。然而,人类心脏中常驻心脏干细胞(hCSCs)的鉴定引起了人们对这类自体细胞在人类疾病管理中的潜在应用的巨大期望。尽管已经进行了1期临床试验,并获得了令人鼓舞的结果,但寻找最强大的hCSC进行心肌再生的研究仍处于初期阶段。该手稿讨论了我们实验室为表征关键生物学变量(定义hCSCs的生长储备)所做的努力。基于永生DNA模板的理论,我们建议保留旧DNA的干细胞代表心肌再生最强大的细胞之一。同样,胰岛素样生长因子-1受体在hCSCs中的表达识别具有较高复制储备的细胞表型。但是,由携带母体DNA的克隆hCSC介导的心室血流动力学和解剖学方面令人印象深刻的恢复突显了该hCSC类在治疗人类心力衰竭方面的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号